bococizumab: Clinical Trials

6 trials of bococizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 16Completed 6

Follow bococizumab: new trials by email Literature Review of bococizumab trials Research Report on bococizumab

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
Bococizumab (PF-04950615; RN316) - Hypercholesterolemia
Phase 1CompletedPfizer752014-04-012019-05-31
A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects
PF-05335810 Dose A, PF-05335810 Dose B, Placebo - Hypercholesterolemia
Phase 1CompletedPfizer1332012-07-012018-12-04
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
PF-04950615 (RN316) - Hypercholesterolemia, Dyslipidemias
Phase 1CompletedPfizer492011-10-012018-07-23
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
PF-04950615 (RN316) - Hypercholesterolemia, Dyslipidemia
Phase 1CompletedPfizer682011-02-012019-01-22
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
4 mg/kg, 0.5 mg/kg - Hypercholesterolemia, Dyslipidemia
Phase 1CompletedPfizer252010-07-012018-03-01
A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects
RN316 - Healthy
Phase 1CompletedPfizer482009-11-012012-07-04

Conditions studied

Hypercholesterolemia (6)  ·  Dyslipidemias (4)  ·  Hyperlipidemias (2)  ·  Lipid Metabolism Disorders (1)  ·  Metabolic Diseases (1)

Sponsors

Pfizer (6)

Countries

United States (6)

Results publications

PMID 37994400, PMID 28181260, PMID 28636184, PMID 29037448